Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 4Phase 1/2 3Phase 1 3Phase EARLY_PHASE1 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 3Melanoma, Cutaneous Malignant 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Opdualag × Clear all
NCT05625399 2026-06-03

RELATIVITY-127

Bristol-Myers Squibb

Phase 3 Active not recruiting
579 enrolled
Dermatologic

Melanoma

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting
360 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT06246916 2026-05-06

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Regeneron Pharmaceuticals

Phase 3 Recruiting
560 enrolled
Dermatologic

Melanoma

NCT05002569 2026-01-08

RELATIVITY-098

Bristol-Myers Squibb

Phase 3 Terminated
1,093 enrolled 15 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡